Swissmedic collaborates with NZ counterpart on device regulation
This article was originally published in RAJ Devices
The Swiss agency for therapeutic products, Swissmedic, has signed an agreement with its New Zealand counterpart, Medsafe, to co-operate on the regulation of medical devices and drugs1.
You may also be interested in...
Companies can have their EU centralized marketing authorization application and submission for an Article 58 opinion (on medicines for use in non-EU countries) reviewed in parallel by the European Medicines Agency. The simultaneous assessment can be helpful when drugs and vaccines are needed for both EU and non-EU populations.
The European Medicines Agency is taking steps to establish infrastructure for monitoring COVID-19 vaccines whenever they reach the European market.
An interim independent assessment of the WHO’s response to the COVID-19 pandemic has supported the organization’s work. But will be it enough to convince critics as the WHO faces the threat of permanently losing funds from its biggest donor, the US?